Product Name :
BI-78D3
Description:
BI-78D3, also known as JNK Inhibitor X, is a potent JNK inhibitor. BI-78D3 dose-dependently inhibits the phosphorylation of JNK substrates both in vitro and in cell. BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes.
CAS:
883065-90-5
Molecular Weight:
379.37
Formula:
C13H9N5O5S2
Chemical Name:
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-3H-1,2,4-triazol-3-one
Smiles :
[O-][N+](=O)C1=CN=C(S1)SC1=NNC(=O)N1C1=CC2OCCOC=2C=C1
InChiKey:
QFRLDZGQEZCCJZ-UHFFFAOYSA-N
InChi :
InChI=1S/C13H9N5O5S2/c19-11-15-16-12(25-13-14-6-10(24-13)18(20)21)17(11)7-1-2-8-9(5-7)23-4-3-22-8/h1-2,5-6H,3-4H2,(H,15,19)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
BI-78D3, also known as JNK Inhibitor X, is a potent JNK inhibitor. BI-78D3 dose-dependently inhibits the phosphorylation of JNK substrates both in vitro and in cell. BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes.|Product information|CAS Number: 883065-90-5|Molecular Weight: 379.37|Formula: C13H9N5O5S2|Synonym:|4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-((5-nitro-2-thiazolyl)thio)-3H-1,2,4-triazol-3-one|BI-78D3| 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-3H-1,2,4-triazol-3-one|Chemical Name: 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-3H-1,2,4-triazol-3-one|Smiles: [O-][N+](=O)C1=CN=C(S1)SC1=NNC(=O)N1C1=CC2OCCOC=2C=C1|InChiKey: QFRLDZGQEZCCJZ-UHFFFAOYSA-N|InChi: InChI=1S/C13H9N5O5S2/c19-11-15-16-12(25-13-14-6-10(24-13)18(20)21)17(11)7-1-2-8-9(5-7)23-4-3-22-8/h1-2,5-6H,3-4H2,(H,15,19)|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Diroximel} site|{Diroximel} Keap1-Nrf2|{Diroximel} Purity & Documentation|{Diroximel} References|{Diroximel} supplier|{Diroximel} Autophagy} |Shelf Life: ≥12 months if stored properly.{{Sonelokimab} site|{Sonelokimab} Interleukin Related|{Sonelokimab} Protocol|{Sonelokimab} In Vitro|{Sonelokimab} custom synthesis|{Sonelokimab} Cancer} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:34856019 |Drug Formulation: To be determined.|HS Tariff Code: 382200|References:|Hein TW, Xu W, Xu X, Kuo L. Acute and Chronic Hyperglycemia Elicit JIP1/JNK-Mediated Endothelial Vasodilator Dysfunction of Retinal Arterioles. Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4333-40. doi: 10.1167/iovs.16-19990. PubMed PMID: 27556216; PubMed Central PMCID: PMC5015966.Alaseem AM, Madiraju P, Aldebeyan SA, Noorwali H, Antoniou J, Mwale F. Naproxen induces type X collagen expression in human bone-marrow-derived mesenchymal stem cells through the upregulation of 5-lipoxygenase. Tissue Eng Part A. 2015 Jan;21(1-2):234-45. doi: 10.1089/ten.TEA.2014.0148. Epub 2014 Oct 23. PubMed PMID: 25091567; PubMed Central PMCID: PMC4292866.Posthumadeboer J, van Egmond PW, Helder MN, de Menezes RX, Cleton-Jansen AM, Beliën JA, Verheul HM, van Royen BJ, Kaspers GJ, van Beusechem VW. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin. Oncotarget. 2012 Oct;3(10):1169-81. PubMed PMID: 23045411; PubMed Central PMCID: PMC3717953.Products are for research use only. Not for human use.|